6 research outputs found
Procediment sonda de gastrostomia endoscòpica percutà nia (PEG)
Sonda de gastrostomia endoscòpica percutĂ nia; PEG; NutriciĂł enteral; Cures infermeresSonda de gastrostomĂa endoscĂłpica percutánea; PEG; NutriciĂłn enteral; Cuidados enfermerosPercutaneous endoscopic gastrostomy tube; PEG; Enteral nutrition; Nursing careAquest document presenta la tècnica de la gastrostomia endoscòpica percutĂ nia, adreçada a aquells pacients que no poden deglutir de forma adequada i han de nodrir-se amb nutriciĂł enteral durant un perĂode de temps
Procediment de cures de sonda de jejunostomia
Procediment de cures; Sonda de jejunostomia; InfermeriaProcedimiento de curas; Sonda de yeyunostomĂa; EnfermerĂaCare procedure; Jejunostomy tube; NurseryAquest document exposa el procediment de cures de sonda de jejunostomia, fa referència a la cura del lloc per on s’ha inserit una sonda a l’inici de l’intestĂ prim (jejĂş) per tal d’administrar nutrients necessaris evitant el pas per la boca, l’esòfag i l’estĂłmac
Clinical, randomized, double blind clinical trial to study the effect of parenteral supplementation with fish oil emulsion in the nutritional support in esophagectomized patients
Introduction: Esophagectomy is a major surgery with a high degree of catabolic and post-surgical inflammatory response accompanied by high morbidity and significant mortality. Post-surgical nutritional support via enteral administration of omega-3 fatty acids has been seen to be effective although its bad tolerance. There are few clinical trials with parenteral omega-3 fatty acids in these patients. We propose to investigate the effect of combining a parenteral fish oil lipid emulsion with the standard enteral nutrition (EN) support. Materials and methods: Prospective, single-center, randomized, double-blind study in esophagectomized patients, and treated after surgery with parenteral lipid emulsions of omega-3 fatty acids or a mixture of omega-6 long-chain triglycerides/short-chain triglycerides 50%. These emulsions will be added to the standard nutritional support in continuous infusion until 5 days of treatment have been completed. Patients will be randomized 1:1:1 in Group A receiving 0.4 g/kg/d of fish-oil lipid emulsion and 0.4 g/kg/d of a lipid emulsion mixture of omega-6 long-chain fatty acids (LCT) plus medium-chain fatty acids (MCT) (total dose of 0.8 g/kg/d of lipid emulsion); Group B receiving 0.8 g/kg/d of fish oil lipid emulsion and Group C receiving 0.8 g/kg/d of LCT/MCT emulsion. The main objective is to determine whether 5 days administration of intravenous omega-3 fatty acid lipid emulsion is effective in normalizing interleukin-6 levels compared with LCT/MCT emulsions, and whether a 0.8 g/kg/d dose is more effective than 0.4 g/kg/d. Secondary outcomes include other inflammatory markers such as C-reactive protein, tumor necrosis factor alpha and interleukin-10, and parameters of morbidity, safety, nutrition and mortality. Samples will be collected at the time when surgery is indicated and on days 0, 1, 3, 5 and 21 to determine inflammatory, nutritional, hepatic and safety parameters. In addition, clinical follow-up will be continued throughout the hospital admision and up to 1 year after surgery. Discussion: Studies of omega-3 fatty acids administered parenterally in esophagectomized patients are scarce. This study proposes to investigate the effect of combining fish-oil lipid emulsions administered parenterally with EN support. Potential benefits include fast incorporation of lipids to the cellular membranes and to the inflammatory cascade, and the use of only 1 pharmaconutrient
ICO-ICS Praxi per al tractament mèdic i amb irradiació de cà ncer gà stric i d'unió esofagogà strica
Tractament mèdic; Tractament amb irradiaciĂł; CĂ ncer de la uniĂł esofagogĂ stricaTratamiento mĂ©dico; Tratamiento con irradiaciĂłn; Cáncer de la uniĂłn esofagogástricaMedical treatment; Irradiation treatment; Esophagogastric union cancerEl cĂ ncer gĂ stric (CG) Ă©s actualment el vuitè tipus de cĂ ncer mĂ©s prevalent a la UniĂł Europea on, segons les estimacions, el 2018 es calculen 80.211 casos diagnosticats en ambdĂłs sexes amb una taxa estimada d'incidència estandarditzada per edat de 6,4 casos per cada 100.000 habitants. En el cas d'Espanya, segons dades d'incidència i mortalitat del projecte GLOBOCAN i de l'Observatori Europeu del CĂ ncer, se situa en novè lloc, desprĂ©s del cĂ ncer de bufeta i el cĂ ncer uterĂ, pel que fa a freqüència. Els objectius d'aquesta guia sĂłn: Desenvolupar, difondre, implementar i avaluar resultats de l'ICO-ICSPraxi de cĂ ncer gĂ stric i d'uniĂł esofagogĂ strica. Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta instituciĂł. Implementar els resultats de la terapèutica en els pacients amb cĂ ncer gĂ stric i d'uniĂł esofagogĂ strica tractats d'acord amb les recomanacions d'aquesta guia.El cáncer gástrico (CG) es actualmente el octavo tipo de cáncer más prevalente en la UniĂłn Europea donde, segĂşn las estimaciones, el 2018 se calculan 80.211 casos diagnosticados en ambos sexos con una tasa estimada de incidencia estandarizada por edad de 6,4 casos por cada 100.000 habitantes. En el caso de España, segĂşn datos de incidencia y mortalidad del proyecto GLOBOCAN y del Observatorio Europeo del Cáncer, se sitĂşa en noveno lugar, despuĂ©s del cáncer de vejiga y el cáncer uterino, en cuanto a frecuencia. Los objetivos de esta guĂa son: Desarrollar, difundir, implementar y evaluar resultados del ICO-ICSPraxi de cáncer gástrico y de uniĂłn esofagogástrica. Disminuir la variabilidad terapĂ©utica entre los pacientes tratados en los diferentes centros de esta instituciĂłn. Implementar los resultados de la terapĂ©utica en los pacientes con cáncer gástrico y de uniĂłn esofagogástrica tratados de acuerdo con las recomendaciones de esta guĂa.Gastric cancer (GC) is currently the eighth most prevalent type of cancer in the European Union where, according to estimates, 80,211 cases diagnosed in both sexes are estimated at an estimated rate of incidence standardized by age of 6.4 cases per 100,000 people. In the case of Spain, according to the incidence and mortality data of the GLOBOCAN project and the European Cancer Observatory, it is placed ninth, after bladder cancer and uterine cancer, as it happens frequently. The objectives of this guide are: Developing, disseminating, implementing and evaluating the results of the ICO-ICSPraxi of gastric cancer and esophagogastric binding. Decrease the therapeutic variability between patients treated at the different centers of this institution. Implement the results of therapeutic treatment in patients with gastric cancer and esphagogastric binding treated in accordance with the recommendations of this guide
Procediment sonda de gastrostomia endoscòpica percutà nia (PEG)
Sonda de gastrostomia endoscòpica percutĂ nia; PEG; NutriciĂł enteral; Cures infermeresSonda de gastrostomĂa endoscĂłpica percutánea; PEG; NutriciĂłn enteral; Cuidados enfermerosPercutaneous endoscopic gastrostomy tube; PEG; Enteral nutrition; Nursing careAquest document presenta la tècnica de la gastrostomia endoscòpica percutĂ nia, adreçada a aquells pacients que no poden deglutir de forma adequada i han de nodrir-se amb nutriciĂł enteral durant un perĂode de temps
Procediment de cures de sonda de jejunostomia
Procediment de cures; Sonda de jejunostomia; InfermeriaProcedimiento de curas; Sonda de yeyunostomĂa; EnfermerĂaCare procedure; Jejunostomy tube; NurseryAquest document exposa el procediment de cures de sonda de jejunostomia, fa referència a la cura del lloc per on s’ha inserit una sonda a l’inici de l’intestĂ prim (jejĂş) per tal d’administrar nutrients necessaris evitant el pas per la boca, l’esòfag i l’estĂłmac